Skip to main content

ProfoundBio Makes $246 Million Deal for Synaffix Linker-Payload Technology

ProfoundBio, a Seattle-Suzhou antibody-drug conjugate company, acquired non-exclusive rights to use novel linker-payload technologies from Amsterdam 's Synaffix. It will make up to $246 million in upfront and milestone payments, plus tiered royalties on sales. ProfoundBio will have rights to use Synaffix's two linker technologies, GlycoConnect™ glycan conjugation and HydraSpace™ polar spacer, for a specific tumor associated antigen along with an option for a second TAA. Two weeks ago, ProfoundBio closed a $55 million funding for its ADC and IO candidates. More details.... Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.